Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 4/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | ABL2 | P42684 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159366 | 1.00 | LIMK1 (0.59) | LIMK1EGFRABL1ABL2CA5A | |
| SCHEMBL2389718 | 0.79 | EGFR (0.57) | LIMK1EGFRABL1ABL2CA5A | |
| SCHEMBL13209220 | 0.79 | EGFR (0.57) | LIMK1EGFRABL1ABL2CA5A | |
| SCHEMBL30672219 | 0.79 | EGFR (0.57) | LIMK1EGFRABL1ABL2CA5A | |
| SCHEMBL6884961 | 0.79 | EGFR (0.57) | LIMK1EGFRABL1ABL2CA5A | |
| SCHEMBL23885372 | 0.78 | LIMK1 (0.47) | LIMK1RETKDR | |
| SCHEMBL30052198 | 0.78 | LIMK1 (0.47) | LIMK1RETKDR | |
| SCHEMBL1923985 | 0.78 | EGFR (0.63) | EGFRCA5AMAPTKDRKDM4E | |
| Hydrochloric Acid SCHEMBL7218016 | 0.78 | EGFR (0.55) | LIMK1EGFRABL1ABL2CA5A | |
| SCHEMBL13960264 | 0.77 | CHEK1 (0.58) | MAPTKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| EP-4125914-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023001133-A1 | PRMT5 INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2021202977-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3110818-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | The Regents of The University of Michigan (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015131005-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-03 | — | — | WO | disclosed |
| US-8193430-B2 | Methods for separating carbon nanotubes | THE UNIVERSITY OF CONNECTICUT (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100044230-A1 | METHODS FOR SEPARATING CARBON NANOTUBES | UNIVERSITY OF CONNECTICUT (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | C5, C9, C1QBP | LIMK1 4012/4885EGFR 2721/4885ABL1 372/4885 |
| US-20100044230-A1 | METHODS FOR SEPARATING CARBON NANOTUBES | FSCN1, TTPA, FLNB | LIMK1 1685/4885EGFR 4863/4885ABL1 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.